Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

DEDICATED PET SYSTEM DETECTS 73% MORE CANCERS OVERALL COMPARED TO DUAL-HEAD COINCIDENCE (SPECT) GAMMA CAMERA, RESEARCHER TELLS RADIOLOGY CONFERENCE

This article was originally published in The Gray Sheet

Executive Summary

A dedicated positron emission tomography (PET) scanner using 18-fluorodeoxyglucose (FDG-18) as a radiotracer detected 73% more cancer sites (121 versus 70) than were identified with an FDG-18 dual-head coincidence gamma camera, researcher Paul Shreve, MD, University of Michigan, reported Dec. 3 at the Radiological Society of North America conference in Chicago.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT009208

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel